Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Substance misuse

Concerns raised over non-medical alprazolam use

Research into the non-medical use of prescription drugs has raised concern that alprazolam use among younger people could be on the rise.

Xanax

Source: GODONG / BSIP / SCIENCE PHOTO LIBRARY

The estimated lifetime non-medical use of alprazolam (Xanax; Pfizer) was 0.32% compared with 1.30% for diazepam

The benzodiazepine alprazolam (Xanax; Pfizer) is being obtained for non-medical use in the UK, particularly among young people, survey results show (4 June 2019)[1].

Alprazolam is not available via the NHS and can only be obtained via private prescription.

Researchers analysed data from 10,019 respondents to the 2017 RADARS Survey of Non-Medical Use of Prescription Drugs, providing a representative sample of the adult UK population.

Overall, the estimated lifetime non-medical use of alprazolam was 0.32% compared with 1.30% for diazepam. Unlike diazepam, for which there was no effect of age on use, the rate of recent use (defined as the past 90 days) was highest among those aged 16–24 years (0.37%) and 25–34 years (0.14%); this was virtually nil in people aged 35 and over.

The findings raised concerns that the popularity of alprazolam could be on the rise among young people. Further research is urgently needed to determine the appeal of the drug in this age group, the researchers said.

“This will enable appropriate public health interventions to prevent short‐term toxicity and long‐term dependence among young adults who are regularly using alprazolam,” they concluded.

Citation: The Pharmaceutical Journal DOI: 10.1211/CP.2019.20206746

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.